Podcasts about biopsies

In this episode, Dr. Stephen Petteruti reexamines the conventional approach to prostate cancer screening, offering a perspective on when a more measured approach may be the best course of action. Many prostate cancers are slow-growing and may never pose a serious threat, yet aggressive treatments continue to be the norm. Instead of rushing into invasive procedures, Dr. Stephen explores alternative strategies, such as advanced imaging, targeted drug therapies, and lifestyle modifications that support long-term prostate health.Listen now for expert insights that will help you make informed decisions and avoid unnecessary procedures. Watch the latest episode of Intellectual Medicine Podcast — Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies.Enjoy the podcast? Subscribe and leave a 5-star review!————————————————————————————————Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website:  www.intellectualmedicine.com LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/  Instagram: https://www.instagram.com/intellectualmedicine  YouTube: https://www.youtube.com/@intellectualmedicinePersonal Website: https://drstephenpetteruti.com/Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.#ProstateHealth #MensHealthMatters #CancerAwareness #HealthTips #MedicalMyths #PreventiveHealth #ProstateCare #WellnessMatters #StayInformed #HealthPodcast

This week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and analytics to determine specific CRN fibrosis level for patients with inconclusive NIT results.  One reason FibroSIGHT is worthy of attention: This is the first time an in-depth analysis of clinical trial biopsy results is being placed at the service of clinical treatment. Another reason: Yukti states that demand for this technique could equal 163,000 cases this year, rising to one million by 2028. The interview starts with Yukti sharing information on her own academic and commercial background and how she came to this role. She describes FibroSIGHT, a service that will provide a highly accurate CRN fibrosis level for patients whose NIT results suggest no clear or consistent finding. Yukti provides practical cues on ordering the test and its reimbursement. Roger shares his long-standing respect for SHG and the clarity it produces. He notes the economic benefit of determining whether a patient has F2 fibrosis, which is indicated for pharmacotherapy, vs.F1, which is not indicated. He sees clear benefit in this analysis. Roger goes on to express concern that any option requiring more biopsies will reduce the number of patients treated, particularly if having this tool encourages payers to require a biopsy as a prerequisite to treatment. He asks whether, over time, HistoIndex might be able to develop a companion analytic to improve these estimates without requiring biopsy. 

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.

The question of choosing between transrectal and transperineal biopsies often arises for prostate biopsies. Dr Louis Lenfant, France, gives us his opinion in this new episode.Discover:The patient centric approachThe switch from transrectal to transperineal prostate biopsyThe indispensable tips and tricks to perform prostate biopsiesHosted by Ausha. See ausha.co/privacy-policy for more information.

When it comes to your health, are you blindly following the standard protocol—or taking control of your own decisions?In this episode, Dr. Stephen Petteruti dives into the controversial world of PSA tests, prostate biopsies, and the hidden risks behind conventional recommendations. Are these procedures truly necessary, or is there a better way to approach prostate health?Dr. Stephen challenges the status quo and explores alternative approaches that prioritize proactive health management over fear-driven decisions.Have you or someone you know faced a difficult decision about PSA tests or biopsies? Drop your thoughts in the comments—let's start the conversation!Tune in to the full episode of Intellectual Medicine Podcast —Don't Biopsy Your Prostate Until You Hear This (Part 2).Enjoy the podcast? Subscribe and leave a 5-star review! ————————————————————————————————Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website:  www.intellectualmedicine.com LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/  Instagram: https://www.instagram.com/intellectualmedicine  YouTube: https://www.youtube.com/@intellectualmedicinePersonal Brand: https://drstephenpetteruti.com/Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan. #ProstateHealth #MensHealthMatters #CancerAwareness #HealthTips #MedicalMyths #PreventiveHealth #ProstateCare #WellnessMatters #StayInformed #HealthPodcast

This week's topics include cell signatures in PCOS, a new technique for prostate biopsies, improving the safety of carotid endarterectomy, and long term risk after TIA.0:41 Long term risk of stroke after TIA1:39 About one in five over the next ten years2:40 Need to continue antiplatelet agents3:33 New technique for prostate biopsy4:36 Biopsy naive men5:35 Microultrasonography used6:35 Limited availability of MRI7:33 Improving safety of carotid endarterectomy8:33 Sonolysis used9:34 Safe and routinely available9:40 Single cell characterization of PCOS endometrium10:40 Cells harvested during proliferative phase11:40 PCOS causes increased risk of endometrial cancer12:54 End

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from March 22-28, 2025.

In this week's VJOncology podcast, we are focusing again on Prostate Cancer Awareness Month, where we have collaborated with experts... The post Prostate cancer awareness month: advances in liquid biopsies appeared first on VJOncology.

We are delighted to drop this pod just as the landmark TRANSLATE trial reads out at the EAU Annual Meeting in Madrid, with a simultaneous publication in Lancet Oncology. This is the world's largest trial of transrectal vs transperineal (TP) prostate biopsy, and reports that TP biopsy has superior cancer detection ability. Is this the end of the road for TRUS biopsy. Hosts Declan Murphy and Renu Eapen are delighted to welcome first and senior authors, Prof Richard Bryant and Dr Alastair Lamb of the University of Oxford to have a detailed discussion about TRANSLATE and what this means for prostate biopsy. `Even better on our YouTube channel Links:Lancet Oncology paperFunders: 

In this episode of Conversations in Lung Cancer Research, Dr. Malinda Itchins, Dr. Annie Wong, and A/Prof Stephen Kao discuss the concept of liquid biopsy, its advantages and limitations, and its clinical applications in lung cancer treatment. They explore how liquid biopsy can provide faster diagnosis and treatment options, especially for patients who cannot undergo traditional tissue biopsies. However, they also address the challenges of sensitivity and the need for further research to integrate liquid biopsy into routine clinical practice.This episode is sponsored by: AstraZeneca  Daiichi Sankyo Australia  SOPHiA Genetics  Thermo Fisher Scientific(00:00) Introduction and Acknowledgements(01:16) Meet the Experts(02:10) Understanding Liquid Biopsy(03:01) Advantages of Liquid Biopsy(06:21) Limitations of Liquid Biopsy(09:15) Clinical Scenarios for Liquid Biopsy(13:15) Barriers and Future Directions(19:39) Conclusion and Thank You

Did you know that prostate biopsies could do more harm than good? In this episode, Dr. Stephen Petteruti reveals why these procedures may lead to unnecessary treatments, complications, and even the spread of cancer cells. Many prostate cancers are non-aggressive and never become life-threatening—so why take the risk?Discover safer, evidence-based strategies for monitoring your prostate health without invasive procedures. Don't let fear make the decision for you—get the facts and take control of your health with confidence.Catch the full episode of Intellectual Medicine Podcast —  Think Twice Before a Prostate Biopsy: The Evidence You Need to Hear.Enjoy the podcast? Subscribe and leave a 5-star review! ————————————————————————————————Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website:  www.intellectualmedicine.com LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/  Instagram: https://www.instagram.com/intellectualmedicine  YouTube: https://www.youtube.com/@intellectualmedicinePersonal Brand: https://drstephenpetteruti.com/ #ProstateHealth #MensHealthMatters #CancerAwareness #HealthTips #MedicalMyths #PreventiveHealth #ProstateCare #WellnessMatters #StayInformed #HealthPodcast

Matthew Dietz, DO, MSEd joins us on OsteoBites to discuss Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: Consensus Recommendations from the Children's Oncology Group Bone Tumour Committee.To advance the care and cure for patients with osteosarcoma and Ewing sarcoma it is necessary to safely improve the amount and usability of diagnostic biopsy material obtained. Indeed, it is anticipated that future osteosarcoma and Ewing sarcoma clinical trials will incorporate molecular biomarkers into treatment risk stratification underscoring the need for optimal tissue collection and processing practices.Historically open/incisional biopsies were the predominant biopsy approach; however, image-guided core needle biopsies have increased in frequency and are safe for patients. These procedures are less invasive and reduce recovery times but have potential limitations. Including the potential for lower tissue volumes, which can limit components of clinical care - including pathologic assessment, diagnostic accuracy, and molecular evaluations - along with the opportunity for research studies with leftover tissue (following informed consent). Additionally, once biopsy material is obtained the handling of the specimen for histologic and subsequent molecular testing requires careful timing, processing and tissue prioritization to ensure all clinical and research opportunities are preserved for the patient.To help optimize these critical elements in patient care the Children's Oncology Group convened a multidisciplinary group of clinical and scientific experts to create reference recommendations for harmonizing tissue acquisition and processing algorithms for osteosarcoma and Ewing sarcoma specimens.

In this weeks VJOncology podcast, three oncology experts delve into the transformative potential of liquid biopsy in breast cancer treatment.... The post Liquid biopsy in breast cancer appeared first on VJOncology.

An AI system trained on breast ultrasound studies showed promise in reducing false positives and biopsies by over 37% and 28%, respectively, while maintaining sensitivity, potentially aiding clinical decision-making. Second, nirsevimab demonstrated effectiveness in preventing RSV infections and hospitalizations among infants, with protection waning over time but remaining significant. Lastly, breast and colon cancer screening rates in the U.S. have surpassed pre-pandemic levels, but cervical cancer screening rates remain concerningly low, highlighting disparities in access to preventive care.

Why is insurance so expensive? Why doesn't insurance pay for everything- a biopsy shouldn't be Sophie's choice • ChatGPT is like the movie Sphere • Faith and gasoline on YouTube

Physician Ash Alizadeh has seen the future of disease diagnosis and monitoring. It is coursing through every patient's veins. Traditionally, biopsies have required invasively gathering tissue – from a lung, a liver, or a fetus. Now it's possible to look for disease without surgery. The DNA is sitting there in the bloodstream, Alizadeh tells host Russ Altman, as they preview the age of liquid biopsies on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Ash A. Alizadeh, MD/PhDConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Ash Alizadeh, a faculty member at Stanford University in Oncology and Medicine.(00:03:39) What is a Liquid Biopsy?Accessing tissues non-invasively using bodily fluids.(00:04:31) Detecting Cancer with Liquid BiopsiesHow localized cancers can be detected through blood samples.(00:06:32) The Science Behind Cancer DNA DetectionThe differences between normal and cancer DNA(00:09:51) How Liquid Biopsy Technology WorksThe technologies behind detecting cancer-related DNA differences.(00:12:36) Advances in Liquid BiopsyNew detection approaches using non-mutant molecules and RNA.(00:14:10) RNA as a Real-Time Tumor MarkerHow RNA reveals active tumor processes and drug resistance.(00:15:55) Tracking Cancer ReccurenceUsing tumor-informed panels to monitor cancer recurrence.(00:16:28)  Adapting to Tumor EvolutionWhy core mutations remain detectable despite cancer changes.(00:17:57) Stability of DNA, RNA, and MethylationComparing durability and reliability of different biomarkers.(00:20:49) Listener Question: Early Cancer DetectionDaniel Kim asks about pre-cancer detection and its potential impact.(00:24:44) Liquid Biopsy in ImmunotherapyUsing liquid biopsy to track and improve immune-based treatments.(00:27:35) Monitoring CAR T-Cell TherapyHow liquid biopsy helps assess immune cell expansion.(00:32:02) EPIC-Seq: Inferring RNA from DNAUsing DNA fragmentation to predict gene expression in tumors.(00:34:49) Targeting Tumor Support SystemsTreatment strategies disrupting the tumor microenvironment.(00:35:52) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Imagine detecting cancer with just a single drop of blood. In this episode of the Beautifully Broken Podcast, host Freddie Kimmel engages in a compelling conversation with Dr. Joshua Routh, MD, a distinguished expert in pathology and molecular oncology. Dr. Routh serves as the Laboratory Director for high-complexity clinical laboratories and holds the position of Associate Professor of Pathology at Midwestern University. He is also the Medical Director for Precision Epigenomics Inc., where he focuses on multi-cancer early detection tests.Together, they examine the science behind EPISEEK, discussing how it analyzes epigenetic markers in the blood to identify potential cancer signals. The conversation covers the importance of methylation in gene expression, the emotional implications of cancer testing, and who should consider getting tested. Dr. Routh emphasizes the need for patient autonomy and informed decision-making in the context of cancer screening. They also explore the advancements in multi-cancer early detection tests, focusing on the technology behind EPISEEK, its cost, and the current lack of insurance coverage. The discussion touches on the implications of abnormal test results, the importance of patient-doctor collaboration, and the need for a holistic approach to health that includes lifestyle factors. Additionally, they discuss the strengths and limitations of current cancer detection technologies and the importance of comprehensive health monitoring.Highlights1:32 Introduction: Personal Reflections on the Importance of Early Cancer Detection3:05 Understanding EpiSeek: A Breakthrough in Liquid Biopsy Technology for Cancer Detection5:40 The Science of EpiSeek: How It Works to Detect Cancer Early8:14 The Role of Methylation in Gene Expression and Its Link to Cancer Growth10:42 Gene Expression and Epigenetics: Why They Matter in Cancer Screening13:20 Interpreting Test Results: What to Do After Receiving an Abnormal Finding16:35 Who Should Get Tested? Assessing Risk Factors, Family History, and Lifestyle19:48 The Emotional Impact of Cancer Screening and the Decision Not to Test22:14 Comparing EpiSeq to Other Multi-Cancer Early Detection Tests25:52 Insurance Coverage for Multi-Cancer Tests: Current Challenges and Future Prospects29:30 Next Steps After an Abnormal Test Result: Further Screening and Actions33:40 The War on Cancer: How Lifestyle Choices Influence Cancer Risk36:15 - Evaluating the Strengths and Limitations of Current Cancer Detection Technologies40:28 - The Importance of Comprehensive Health Monitoring Beyond Single TestsUPGRADE YOUR WELLNESSEpiSeq Test: https://www.precision-epigenomics.com/episeqExclusive $50 Discount Offer (Valid Until August 1, 2025): https://www.precision-epigenomics.com/offerSilver Biotics Muscle Cream: https://www.silverbiotics.com (Use Code: BEAUTIFULLYBROKEN for Discount)Saga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

Dr. Brooke Britton joins James Jacobson to demystify the mitotic index—a critical factor in understanding your dog's cancer diagnosis. Learn how this number, derived from a tumor biopsy, influences treatment decisions and prognosis for various types of dog cancers like mast cell tumors, soft tissue sarcomas, and melanomas. Dr. Britton shares her expertise in interpreting pathology reports and navigating the nuances of cancer care for your beloved pet. Topics Covered:  What is the mitotic index?  How pathologists calculate and report mitotic index.  When mitotic index is critical for treatment decisions.  The role of biopsies in cancer diagnosis and care.  Why tumors behave unpredictably and what that means for your dog.  Key Takeaway:  The mitotic index is just one of many factors in dog cancer care, but it can play a vital role in understanding tumor behavior and guiding treatment.  Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question.   Related Links:  An article on mitotic index: https://www.dogcancer.com/articles/diagnosis-and-medical-procedures/mitotic-index/  Chapters:  00:00 Introduction  00:30 What is Mitotic Index?  01:30 How Mitotic Index Is Calculated   03:00 Tumor Heterogeneity   07:00 Mitotic Index and Prognosis   11:00 High vs. Low Mitotic Index   15:00 Biopsy and Treatment Decisions   19:00 Re-Biopsy Insights   21:00 Wrap-Up    Get to know Dr. Brooke Britton: https://www.dogcancer.com/people/brooke-britton-dvm-dacvim-oncology/  For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Bill Morice is the President and CEO of Mayo Clinic Labs and a professor of pathology at Mayo Clinic. Returning to the program for two segments, here he discusses liquid biopsies, their efficacy and how they'll change detecting and treating cancer. And what do humans need to be concerned over with avian influenza... or, bird flu. The Christopher Gabriel Program ----------------------------------------------------------- Please Like, Comment and Follow 'The Christopher Gabriel Program' on all platforms: The Christopher Gabriel Program is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- The Christopher Gabriel Program | Website | Facebook | X | Instagram | --- Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Can a urine test reduce unnecessary prostate biopsies?

 I recently had the chance to join Dr. DeAngelo Webster on the Practice Biopsy podcast to talk about leadership in dentistry—what it is, what it isn't, and how anyone can step into it, title or not. We discussed how great leaders multiply impact, why trust is the foundation of influence, and how the TEACH model helps create systematic, measurable growth. Whether you're leading a practice, a team, or just yourself, this conversation breaks down leadership into real, actionable steps. Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/matrika/funk-style - License code: KUYOIZCBFCF1FOMP https://uppbeat.io/t/roo-walker/bolt - License code: RS1AU6Y5DGD5A3H8.

If you've tried everything to heal chronic Lyme, fatigue, or stubborn health issues but still feel stuck, the problem isn't you. It's that conventional medicine often misses the invisible root causes: trapped emotions, EMF toxicity, and energy blockages.  Dr. Michael Rankin Sr., a naturopathic doctor and bioenergetics pioneer, shares why nothing should last more than six months if you're asking the right questions. With over 40 years in holistic health, Dr. Rankin reveals how bioenergetic scans, PEMF therapy, and emotional detox can reverse conditions mainstream doctors call “incurable.” From dissolving bone spurs to healing insomnia, his clinic uses modern tech like BioResonance and ZYTO to map the body's energy field—no invasive tests needed.   “If you have a condition for more than six months, someone's not asking the right questions. Nothing lasts more than six months.” ~ Dr. Michael Rankin Sr.   In This Episode: - Dr. Rankin's journey into bioenergetics - Bioenergetic scans vs. blood tests: Which reveals more? - How bioenergetic testing works - Biopsies, and other hidden health bombs - Detoxing the liver and regenerating Tissues - Why root canals and scars may be blocking your healing - How radionics and bioresonance can improve sleep - PEMF devices and grounding - The Infinity Bed: deep sleep and beyond - The magic of PEMF and QRS devices - Castor oil: the detox protocol you're missing - QRS PEMF mats and how they work - The power of positive affirmations For more information, visit https://www.myersdetox.com    Ready to detox heavy metals? Take the quiz: http://www.heavymetalsquiz.com    Resources Mentioned in This Episode: - QRS PEMF Mat: Get a discount at https://testingcancer.com. - Puori PW1 Whey Protein: Get 20% off today! Visit https://puori.com/Wendy and enter code WENDY at checkout. - Chef's Foundry P600 Cookware: Get an exclusive discount today! Visit https://bit.ly/MyersDetox to claim your special offer. Dr. Jockers Functional Nutrition Podcast: Search "Dr. Jockers" on your favorite podcast platform: https://podcasts.apple.com/us/podcast/dr-jockers-functional-nutrition/id1497791107    About Dr. Michael Rankin Sr. Dr. Michael Rankin Sr. is a naturopathic doctor and director of the Kelly Metabolic Center. With decades of experience in bioenergetic medicine, he specializes in resolving emotional trauma, cancer, and chronic pain using non-invasive technologies like BioResonance, ZYTO, and PEMF therapy. A former conventional medic turned holistic pioneer, Dr. Rankin's work bridges ancient wisdom and modern science—proving that energy, not drugs, holds the key to lasting healing. His clinic offers remote bioenergetic scans and personalized protocols to detox scars, reverse calcification, and restore vitality. Learn more about Dr. Rankin at https://testingcancer.com/    Disclaimer The Myers Detox Podcast was created and hosted by Dr. Wendy Myers. This podcast is for information purposes only. Statements and views expressed on this podcast are not medical advice. This podcast, including Wendy Myers and the producers, disclaims responsibility for any possible adverse effects from using the information contained herein. The opinions of guests are their own, and this podcast does not endorse or accept responsibility for statements made by guests. This podcast does not make any representations or warranties about guests' qualifications or credibility. Individuals on this podcast may have a direct or indirect financial interest in products or services referred to herein. If you think you have a medical problem, consult a licensed physician.

Click here to receive today's free gift on the Radio Page: The Parable of the Prodigal Son – Enjoy compelling life applications and relevant lessons on grace, anger, and compassion. The Parable of the Prodigal Son tackles issues we all face today, and is perfect for new Christians wanting to study God's grace and forgiveness to all, and anyone needing a fresh reminder of the grace Christians are called to extend to all. Use the coupon code: RADIOGIFT for free shipping!*Limit one copy per person* --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

In this episode of the Radiology Podcast, Dr. Lauren Kim speaks with Dr. Lama Dawi about a groundbreaking study comparing liquid biopsy and CT imaging in assessing tumor burden. They explore the strengths, limitations, and future of liquid biopsy in cancer diagnostics and precision medicine. Can it replace CT scans? Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases. Dawi et al.Radiology 2024; 313(2):e232674. 

Hour 3--J&J Show Monday 2/3/25-- 92.9 FM ESPN full biopsy on the Luka Doncic Trade with J&J + Jaren Jackson Jr ascension is real & happening on 92.9 FM ESPN full 2484 Mon, 03 Feb 2025 20:11:02 +0000 HyGjY9DncmZk0VsNx1nHMoZG7O71w4Iq sports Jason & John sports Hour 3--J&J Show Monday 2/3/25-- 92.9 FM ESPN full biopsy on the Luka Doncic Trade with J&J + Jaren Jackson Jr ascension is real & happening on 92.9 FM ESPN Local columnists and hoops insiders Jason Smith and John Martin appear daily 11am - 2pm on 929FM ESPN/680AM! 2024 © 2021 Audacy, Inc. Sports False https://player.amperwavepodcasting.com?feed-link=https%3A%2F%2Frss.amperwave.net%

More than a million breast biopsies are performed annually in the United States, according to the Agency for Healthcare Research and Quality. The need to ensure diagnostic accuracy is great. Alycen Wiacek, Ph.D., motivated by the impact breast cancer has had on her family and a desire to make a difference, is conducting research to help make biopsies more accurate through engineering and augmented reality. In this episode of Further Together, host Matthew Underwood talks to Wiacek about her research. Wiacek is an assistant professor at Oakland University. In her lab, the Medical Acoustics for Global Health Imaging and Clinical Translation (MAGIC), she and her students are developing a system that integrates various imaging modalities into AR to assist in the targeted biopsy of breast masses. This approach with AR means images and information can be displayed directly in the physician's field of view to better guide the biopsy process. Her research is supported by an ORAU Ralph E. Powe Junior Faculty Enhancement Award in partnership with the Augmented Reality for Enterprise Alliance (AREA).

To book a session with Dr. Lederman: http://connectionDocs.com To order the breathing device to help anxiety: https://webekalm.com/discount/ChefAJ Breaking The Silence: Sharing My Lung Cancer Diagnosis With You https://www.youtube.com/watch?v=36XThEsfLCg&t=1831s Home From the Hospital: My Lung Biopsy Adventure https://www.youtube.com/watch?v=Z1qlb9hwiLk&t=2763s https://www.youtube.com/watch?v=vQd0NcmQZSc&t=3s https://www.youtube.com/watch?v=vQd0NcmQZSc&t=3s ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. BIO: Matthew Lederman, MD, is a board-certified Internal Medicine Physician and a pioneering thought leader in holistic health. Renowned for his innovative integration of plant-based nutrition, Nonviolent Communication (NVC), trauma-informed care, and lifestyle medicine, Dr. Lederman's work highlights the profound interconnectedness of physical, emotional, and relational well-being. AI Connection Coach: http://kinectin.com Book: “WELLNESS TO WONDERFUL: 9 Pillars for Living Healthier, Longer, and with Greater Joy” https://a.co/d/6GfDdcL Social Media: Instagram: https://www.instagram.com/TheConnectionDocs Substack Newsletter: https://connectionDocs.substack.com Facebook: https://www.facebook.com/connectionDocs X: https://x.com/connectionDocs

Hi Friends, I just got home from the hospital. I had a core needle biopsy today to assess my lung tumor in order to stage my cancer. I do have a slight pneumothorax and some pain but nothing I can't handle. If you want to know about how I was diagnosed with Stage 3 Lung Cancer watch here: https://www.youtube.com/watch?v=36XThEsfLCg&t=1859s and here: https://www.youtube.com/watch?v=vQd0NcmQZSc&t=62s If you'd like to be coached by Susanna: https://susannahallhealthcoaching.com/ If you'd like to watch my FREE upcoming series Thriving in The Face of Cancer be sure you are on my mailing list: https://chefaj.com/ ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes.

In this AANEM podcast, Dr. Andrés De León interviews neuromuscular pathology experts Dr. Aziz Shaibani and Dr. Marcus Pinto about the current state and value of muscle and nerve biopsies in clinical practice. The discussion covers essential topics including proper indications for biopsies, technical considerations in choosing biopsy sites, staining techniques, and the impact of advancing genetic testing on diagnostic approaches. Dr. Shaibani emphasizes that while genetic testing has reduced some muscle biopsy indications, biopsies remain crucial for certain conditions like inflammatory myopathies and mitochondrial disorders. Dr. Pinto details specific scenarios where nerve biopsies are invaluable, particularly in diagnosing vasculitic neuropathy and amyloidosis. Both experts share insights on the complementary role of muscle and nerve biopsies in conditions like systemic vasculitis and discuss how modern diagnostic tools like myositis antibody testing and genetic panels are changing but not eliminating the need for tissue diagnosis.

It might be time to rethink your liver biopsy technique. Transfemoral transcaval core-needle liver biopsy has demonstrated key advantages over the transjugular approach and has become increasingly popular in recent years. Interventional radiologists Dr. Jacob Cynamon and Dr. Kapil Wattamwar join host Dr. Sabeen Dhand to discuss the inception and advantages of their novel approach. --- This podcast is supported by: Reflow Medical https://www.reflowmedical.com/ --- SYNPOSIS The doctors start with how they began using the transfemoral transcaval approach, along with the literature they published following adoption of this novel technique shortly thereafter. Dr. Cynamon and Dr. Wattamwar then go on to discuss the technique in detail, providing a thorough step-by-step and pausing to mention key considerations. The episode concludes with the doctors emphasizing the safety and efficacy of the transfemoral transcaval approach, citing specific findings and sharing exemplary cases. --- TIMESTAMPS 00:00 - Introduction 05:47 - Percutaneous vs. Transvenous Biopsies 08:56 - Evolution of Transfemoral Biopsies 12:41 - Comparing Transjugular and Transfemoral Approaches 24:52 - Pre-Procedural Imaging and Sheath Selection 29:23 - Complications and Case Studies 35:46 - Transcaval Biopsy Technique 45:00 - Conclusion --- RESOURCES Cynamon, 2016. Transfemoral Transcaval Core-Needle Liver Biopsy: An Alternative to Transjugular Liver Biopsy: https://pubmed.ncbi.nlm.nih.gov/26723528/ Wattamar, 2020. Transjugular versus Transfemoral Transcaval Liver Biopsy: A Single-Center Experience in 500 Cases: https://pubmed.ncbi.nlm.nih.gov/32798119/ Wattamar, 2022. The Use of the Transfemoral Transcaval Liver Biopsy Technique for Biopsies of Hepatic Masses: https://pubmed.ncbi.nlm.nih.gov/36182256/ Wattamar, 2022. Transcaval Creation of a Portal Vein Target for Transjugular Intrahepatic Portosystemic Shunt in a Patient with Portal Vein Thrombosis: https://pubmed.ncbi.nlm.nih.gov/34448032/

Certain CD4+ T-cell subtypes play a role in asthma. Characterizing asthma endotypes in diverse groups is important to help develop effective therapies for youth with asthma. Author Juan C. Celedon, MD, DrPH, University of Pittsburgh, Department of Pediatrics, discusses this and more with JAMA Deputy Editor Kristin L. Walter, MD, MS. Related Content: Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the ESSENCE trial, the Phase 3 trial demonstrating that semaglutide regresses fibrosis levels in some MASH patients.  The conversation begins with each panelist sharing a word or short phrase they felt best captured their feelings about TLM2024. Next, panelists review the meeting's most consequential paper, the ESSENCE Trial. Naim starts by describing ESSENCE, a Phase 3 trial with semaglutide demonstrating significant levels of fibrosis regression in non-cirrhotic MASH patients. Jörn adds the hopeful note that NITs performed as well as or better than biopsy in this trial, which he hopes will speed the transition in diagnostic approaches and tools. Jeff and Mike agree that from the patient's perspective, ESSENCE will be seen as a milestone in MASH therapy: the proof that a second drug can succeed in MASH. As the conversation ends, Roger notes that approval of a second agent for a particular disease often leads to dramatic growth in overall drug treatment by changing the pivotal question from whether to treat with a drug to which choice to prescribe. 

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers how the anticipated approval of a second MASH drug without biopsy might affect clinical trials and discusses two recent publications on patient genotyping and patient clusters. The conversation starts with Roger asking the group whether the presence of two approved MASH medications that do not require biopsy will make recruiting clinical trials that require them more challenging. The group doubts this will not add a significant new challenge to already-challenging trial recruitment. Naim comments that while this is a concern, it is already factored into trial schedules and that, given the number of patients available for trial, this should be highly manageable. Michelle discusses the importance of risk stratification in overall trial enrollment and this issue. Jeff and Mike agree that while this is a concern, it is part of a broader concern about the use of biopsy and should not in itself be a primary focus in terms of trial design at this point in time. Naim introduces two other topics he considers worthy of consideration: the impact of synergy between resmetirom and GLP-1 agonists and the importance of different genetic polymorphisms in predicting the impact of drugs on specific patients. On synergy, he comments that MAESTRO-NASH data suggests that the presence of a GLP-1 does not affect the impact of resmetirom on fibrosis level. On the second point, he notes that several papers looked at major genotypes like PNPLA3 and HD17N13 and specifically cites a late-breaker from Arun Sanyal indicating that g-allele status may impact MASH independent of weight or insulin. Michelle mentions a recent paper in Nature identifying distinct clusters of patients based on how their SLDs progress over time, with a two-cluster solution indicating patients with concomitant diabetes and obesity vs. those without these two concomitant diseases. Roger shares a key point from each paper on treatment in the US. Data in the PNPLA3 paper might suggest that the course of disease in Hispanics, who have high levels of g-allele abnormalities, might be different from other ethnic groups with far lower abnormality rates. He also notes that the faster disease progression in the non-metabolic cluster highlights the importance of learning more about Lean MASH and how to treat it, since faster progression of disease suggests later diagnosis and higher morbidity, mortality and treatment costs levels.

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the late-breaker presentation on efimosermin, a q4w FGF-21 agent and the "FDA Corner" session. Jörn begins the discussion by highlighting a paper from the later breaker session on efimosfermin alfa, an FGF-21 agent dosed q4w. He notes that after only six doses (24 weeks), efimosfermin alfa demonstrated significant increases in fibrosis regression and lowering NAS score. To Jörn, this result, coupled with others on efruxifermin and pegozafermin, suggest that FGF-21s are likely to play a significant role in MASH therapy once approved. After Roger and Mike note their enthusiasm about the drug class and this study, Jörn mentions a study with 96-week efruxifermin that data demonstrates prolonged efficacy. As he points out, this matters because while studies of an earlier FGF-21 candidate suggested that antibodies might develop in FGF-21 therapy, that does not appear to be an issue here. Mike asks the group why they feel placebo performs so well in clinical trials. Jörn suggests that working with a compassionate clinical care team in dealing with the patient leads to better performance on diet and exercise and, as a result, increased placebo response to what we might find in general community practice.Michelle praises the FDA Corner session, particularly the agency's transparency and willingness to engage industry and academia in finding paths to move away from biopsy. She also notes some of the practical challenges inherent of moving away from biopsy using data from earlier trials with an outmoded histology reader setup. She is optimistic about the scientific community coming together to address these issues. Jeff praises the agency for an "amazing" session. 

Send us a textIn our latest episode of MedStar Health DocTalk, Debra Schindler talks with MedStar Health breast surgeon, Maen Farha, MD, medical director of the Breast Center at MedStar Good Samaritan Hospital in Baltimore, about the most common breast cancer diagnosis: ductal carcinoma in situ (DCIS). Learn more about the contained, early-stage disease, the intricacies of diagnosis, and the personalized treatment options available. Dr. Farha shares valuable experience and a wealth of knowledge with hope for outstanding results, possible with proper care.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Hi Friends, I just got home from the hospital. I had a core needle biopsy today to assess my lung tumor in order to stage my cancer. I do have a slight pneumothorax and some pain but nothing I can't handle. If you want to know about how I was diagnosed with Stage 3 Lung Cancer watch here: https://www.youtube.com/watch?v=36XThEsfLCg&t=1859s and here: https://www.youtube.com/watch?v=vQd0NcmQZSc&t=62s If you'd like to be coached by Susanna: https://susannahallhealthcoaching.com/ If you'd like to watch my FREE upcoming series Thriving in The Face of Cancer be sure you are on my mailing list: https://chefaj.com/ ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes.

ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Website: http://connectionDocs.com Calming device: https://webekalm.com/d Upcoming Course: http://connectionDocs.com/courses Podcast: http://webeParents.com AI Connection Coach: http://kinectin.com Book: “WELLNESS TO WONDERFUL: 9 Pillars for Living Healthier, Longer, and with Greater Joy” https://a.co/d/6GfDdcL Social Media: Instagram: https://www.instagram.com/TheConnectionDocs Substack Newsletter: https://connectionDocs.substack.com Facebook: https://www.facebook.com/connectionDocs X: https://x.com/connectionDocs BIO: Matthew Lederman, MD, is a board-certified Internal Medicine Physician and a pioneering thought leader in holistic health. Renowned for his innovative integration of plant-based nutrition, Nonviolent Communication (NVC), trauma-informed care, and lifestyle medicine, Dr. Lederman's work highlights the profound interconnectedness of physical, emotional, and relational well-being. As a certified Nonviolent Communication Trainer through the Center for Nonviolent Communication (CNVC), Dr. Lederman combines Polyvagal Theory, Somatic Awareness Principles, and Pain Reprocessing to empower individuals to heal from within. His approach helps people address the root causes of chronic health challenges, fostering emotional resilience and cultivating meaningful connections. Dr. Lederman is the co-host of the webe Parents podcast, a platform dedicated to equipping parents with tools and insights to foster emotional connection, resilience, and well-being in their families. His latest book, Wellness to Wonderful, weaves together medical science, psychology, spirituality, and life wisdom to guide individuals toward lasting health, vibrancy, peace, and joy. He has co-authored six books, including the New York Times Bestseller Forks Over Knives Plan, and was featured in the acclaimed documentary Forks Over Knives. Through these works, he has shared his transformative approach to wellness with audiences around the globe. In addition to his roles as a clinician, educator, speaker, and corporate advisor, Dr. Lederman has served as Vice President of Medical Affairs at Whole Foods Market, lectured for eCornell, and provided adjunct faculty instruction in medical schools. He also co-created the webe kälm device, designed to promote emotional regulation and soothe the nervous system. As the co-founder of Connection Docs, Dr. Lederman integrates the principles of Nonviolent Communication and emotional health with practical tools to enhance relational and self-connection. Through this groundbreaking platform, he continues to empower individuals and families to strengthen their emotional well-being and build meaningful relationships.

Don't get to the end of this year wishing you had taken action to change your business and your life.Click here to schedule a free discovery call for your business: https://geni.us/IFORABEShop-Ware gives you the tools to provide your shop with everything needed to become optimally profitable.Click here to schedule a free demo: https://info.shop-ware.com/profitabilityUtilize the fastest and easiest way to look up and order parts and tires with PartsTech absolutely free.Click here to get started: https://geni.us/PartsTechTransform your shop's marketing with the best in the automotive industry, Shop Marketing Pros! Get a free audit of your shop's current marketing by clicking here: https://geni.us/ShopMarketingPros In this episode, Lucas and David Roman are joined by Scott Hicks, an industry expert. Scott provides insights into network diagnostics, explaining the simplicity of using basic tools like a multimeter for solving most network issues. David and Scott also discuss their contrasting willingness to experiment and learn. 00:00 Wife leaves class due to inappropriate jokes.05:04 Consider change; avoid repetitive conversations.08:49 Small show rebrand became huge event success.11:59 Subaru misfire: Coil connector issue discovered.15:11 Overthinking causes unnecessary complications and mistakes.18:51 GM evolving automobile network infrastructure strategies.21:46 Tinkers for 10% performance boost without manuals.23:48 Skeptical of washing machine solutions. Limited effort.27:13 It wasn't going to fix the issue.30:51 Overseas manufacturing benefits consumers with cheap EVs.35:16 Ensuring transparency for car repair data access.36:02 Lies frustrate; protocol offers access amid constraints.39:08 Approach affects perception; manufacturers willing to collaborate.43:15 Dealers influence training content, favor resistance testing.46:10 Depopulation conspiracy for land acquisition.49:41 Saw Scott; commented on his gray hair.55:11 Biopsy and scope for potential throat cancer.56:00 George's painful diverticulitis surgery with tube.58:59 Foam roller relieves back pain effectively.

In this week's podcast, Neurology Today's editor-in-chief highlights articles on a study highlighting three-year outcomes for patients with anti-NMDAR encephalitis, an analysis comparing the diagnostic efficacy of skin biopsies vs. CSF tests for human prion diseases, and the ways in which a graduate degree in public health and/or business administration can shape career pathways for neurologists.  

Welcome back to The Genetics Podcast! Today, we're joined by Dr. Luis Diaz, Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering and a White House Appointee to the National Cancer Advisory Board. Dr. Diaz's career has been defined by his commitment to translating cutting-edge cancer genomics into clinical practice. In this episode, he and Patrick dive into his groundbreaking trial on mismatch repair (MMR)-deficient rectal cancer, along with his pioneering work on liquid biopsies, immunotherapies targeting tumors with microsatellite instability, and advancements in precision oncology. To learn more about Dr. Diaz and his work, visit his research page here: https://www.mskcc.org/research-areas/labs/luis-diaz.

We were a podcast divided this week as we discussed an episode involving the A Team trying to rescue their old doctor from Vietnam!  Join us for the fighting, the screaming, and the swearing as we navigate the dark underbelly of a sovereign nation!Episode Title: The Island Original Airdate: November 13th, 1984Find our 2023 & 2024 Summer Series from Episodes 207-211 & 240-245Find The Airwolf Years from Episodes 96 - 189Find The Knight Rider Years from Episodes 1 - 95-----We'll be back on December 4th, to discuss The A-Team Season 3 Episode 9: Showdown! The A-Team is available to rent on Amazon Prime, Apple TV, and Fandango at Home.  But don't forget to check your local library for physical copies of the show too!-----The 80's Years Opening & Closing Theme by: Steve Corning, http://thinkfishtank.comThe 80's Years Logo Design by: Luke LarssonFollow us on Facebook: https://www.facebook.com/the80syearsInstagram: @the80syearsThreads: @the80syearsBluesky: @the80syearsTikTok: @the80syearsEmail us: letusblowyourmind@gmail.comCall our Hotline: (207) 835-1954

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how to differentiate between CAA-RI and PACNS. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

Liquid biopsies and circulating tumor DNA are changing and improving the way cancer is detected and treated. In this episode, Sameek Roychowdhury, PhD, MD, explains the basics of circulating tumor DNA, how it's being used at the James, his lab's clinical trials, and the promising future. “When a normal cell and a cancer die they sheds fragments of their DNA,” he said. “Cancer can be detected in the blood by looking for these fragments and this is becoming an important research tool and treatment tool for the care of cancer patients.” For example, about 50 percent of cancer patients who have a tumor surgically removed will have a recurrence. And it's very difficult to determine which patients will have the recurrence. Minimally invasive liquid biopsies after surgery “helps us stratify and determine patients with a lesser recurrence risk who won't need chemotherapy or immunotherapy treatment versus those patients who need even more treatment than we've normally given them in the past.” Monitoring circulating tumor DNA “also becomes part of the surveillance program and we'll do a precise test every three months that measures fragments in the blood,” Roychowdhury said, adding that finding a recurrence of cancer from these fragments, months before it would appear on more traditional scans “allows us to make a diagnosis about the molecular drivers of the cancer and we can begin treatment earlier and better understand which treatment options will work best.”

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss the underlying pathophysiology and how to diagnose primary angiitis of the CNS in clinical practice. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how cerebral amyloid angiopathy and CAA-RI present in clinical practice and how to make a diagnosis. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

Is your microwave ablation technique up to date? Dr. Ed Kim sits down with guest-host Dr. Kavi Krishnasamy to explore cutting-edge techniques in tumor ablation, with a focus on hepatocellular carcinoma (HCC) treatment with microwave. Dr. Ed Kim is the Director of Interventional Oncology and Professor of Radiology and Surgery in the Division of Vascular and Interventional Radiology at the Mount Sinai Medical Center. --- This podcast is supported by an educational grant from: Varian, a Siemens Healthineers company https://www.varian.com/ --- SYNPOSIS The doctors discuss microwave ablation, radiation segmentectomy, and the decision-making algorithms for choosing appropriate procedures based on lesion characteristics. Dr. Kim touches on the complexities of ablation near the diaphragm and subcapsular lesions, emphasizing the impact of practitioner skill and experience on outcomes. Recent advancements in ablation technologies, software, and device-specific versus device-agnostic applications are also highlighted, along with the importance of post-contrast scans and ultrasound skills. Dr. Kim also delves into emerging technologies such as HistoSonics, augmented reality/virtual reality, and immunotherapy synergies. The doctors underscore the need for a multidisciplinary approach for optimizing patient outcomes and pushing the field toward future innovations. --- TIMESTAMPS 00:00 - Introduction 04:28 - Standardizing Ablation Algorithms 07:51 - Suboptimal Lesion Locations 13:06 - Device Selection and Properties 22:49 - Ablation Planning Software 32:53 - Real-Time Visualization 44:48 - Biopsy and Ablation Techniques 52:14 - Future of Ablation Technology --- RESOURCES Dr. Ed Kim's Publications: https://scholars.mssm.edu/en/persons/edward-kim ACCLAIM Trial: https://www.sio-central.org/ACCLAIM-Trial A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4093 Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA3501 SIR welcomes results of COLLISION Trial, presented at the 2024 ASCO Annual Meeting: https://www.sirweb.org/media-and-pubs/media/news-release-archive/collision-trial-06032024/ HistoSonics: https://histosonics.com/

Dr. Justin Abbatemarco talks with Dr. Ahmad Nehme about the complexities of diagnosing and differentiating between Cerebral amyloid angiopathy-related inflammation and biopsy-positive primary angiitis of the central nervous system. Read the related article in Neurology. Disclosures can be found at Neurology.org.

Should you really get that cancer screening your doctor recommends? In this first of a series of  "Ask Dr. Katie Anything" episodes, Dr. Katie Deming, a former radiation oncologist tackles your pressing questions about cancer screening, biopsies, and genetic testing. Drawing from her 20 years of experience in conventional oncology and her current holistic practice, she offers a balanced perspective that helps you make informed decisions about your health.Dr. Katie Deming shares honest insights about how to trust your intuition while considering medical evidence, and explains why there's rarely a one-size-fits-all answer when it comes to cancer prevention and screening. She also addresses the challenging dynamics that often arise between patients, doctors, and family members when making important health decisions.Listen in to learn how to make confident decisions about your health that align with your values and lifestyle.Pick up your free guide - 3 Things you need to know about cancer:  https://www.katiedeming.com/cancer-101/Send us a textTransform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatie Don't Face Cancer Alone"The 6 Pillars of Healing Cancer" workshop series provides you valuable insights and strategies to support your healing journey - Click Here to Enroll MORE FROM KATIE DEMING M.D. Free Guide - 3 Things You Need to Know About Cancer: https://www.katiedeming.com/cancer-101/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: The.Conscious.Oncologist Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.